Nuvation Bio
Oleg Nodelman is the Founder and Portfolio Manager of EcoR1 Capital LLC, a biotech-focused investment advisory firm established in 2013, which invests in companies at all stages of research and development. With nearly twenty years of experience in biotech investing, Mr.
Nodelman has expertise in all aspects of investment management and deep roots in the biotech and scientific communities. Before founding EcoR1, Mr. Nodelman was a portfolio manager at BVF Partners, one of the first hedge funds dedicated to the biotechnology sector. He currently serves as a Board Member for Prothena (NASDAQ: PRTA), a clinical-stage neuroscience company focused on the discovery and development of novel therapies. Mr. Nodelman is also the CEO and Chairman of Panacea Acquisition Corp (NYSE: PANA). Mr. Nodelman has a Bachelor of Science in Foreign Service with a concentration in Science and Technology from Georgetown University. (Mr. Nodelman will become a director upon completion of the pending merger between Nuvation Bio and Panacea Acquisition Corp.)
This person is not in the org chart
This person is not in any offices
Nuvation Bio
2 followers
Nuvation Bio (NYSE: NUVB) is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio’s proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer.